6855 — Ascentage Pharma International Share News
0.000.00%
Last trade - 00:00- HK$11.38bn
- HK$11.63bn
- CNY574.12m
Brief: Ascentage Pharma Announces Pricing Of U.S. Initial Public Offering
HK-listed Ascentage set for best day in near 5 months on US listing plan
Takeda-backed Ascentage Pharma targets $1.75 bln valuation in US IPO (updated)
China's Ascentage Pharma targets $149 mln raise in US IPO
Brief: Ascentage Pharma Group International Files For U.S. IPO
Brief: Ascentage Says NMPA Accepts New Drug Application For Novel Bcl-2 Inhibitor Lisaftoclax
Brief: Ascentage Pharma Group International Posts H1 Net Income Of HKD 163 Million
Brief: Ascentage Pharma Says Olverembatinib Approved For Commercialization In Macau China
Brief: Ascentage Pharma Received $100 Mln Option Payment From Takeda
Brief: Ascentage Pharma Signs Option Agreement With Takeda To Enter Into Exclusive Global License For Olverembatinib
Brief: Ascentage Pharma Group International Announces Exclusive Option Deal With Takeda International
Brief: Ascentage Pharma Group International Says To Issue And Allot 24.3 Mln Subscription Shares
Brief: Ascentage Pharma Group International Announces Acquisition Of 80,000 Shares By Chairman
Brief: Ascentage Pharma Group International Announces Acquisition Of Shares By Directors
Brief: Ascentage Pharma Group International Gets FDA Clearance To Start Phase 3 Clinical Trial For Olverembatinib
Brief: Ascentage Pharma Group International Says Class 1 Innovative Drug Olverembatinib Approved By NMPA
Brief: Ascentage Pharma Group International Says HY Revenue Rmb142.7 Million
Brief: Ascentage Pharma Group International Receives Clearance From U.S. FDA
Brief: Ascentage Pharma Group International Says NMPA Approved Phase 3 Study Of Olverembatinib